Philip Breitfeld MD
Managing Director, The Breitfeld Group, LLC
Join to View Full Profile
2115 Meadowcreek DrDurham, NC 27705
Dr. Breitfeld is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1982 - 1985
University of Rochester Medical CenterResidency, Pediatrics, 1979 - 1982
University of Rochester School of Medicine and DentistryClass of 1979
Princeton UniversityAB, Chemistry, 1971 - 1975
Certifications & Licensure
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma Start of enrollment: 2001 Nov 01
Publications & Presentations
PubMed
- 25 citationsRisk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology GroupLeo Mascarenhas, Elizabeth R. Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Cancer. 2019-08-01 - 68 citationsFactors associated with failure of oncology drugs in late-stage clinical development: A systematic reviewDenis Leonardo Fontes Jardim, Eric S. Groves, Philip P. Breitfeld, Razelle Kurzrock
Cancer Treatment Reviews. 2017-01-01 - 73 citationsRandomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the C...Leo Mascarenhas, Elizabeth Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson
Journal of Clinical Oncology. 2010-10-20
Press Mentions
- Fannin/Allterum Awarded $2 Million SBIR Phase II Grant from NIH to Advance Monoclonal Antibody for Treating Childhood LeukemiaMay 8th, 2023
Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior LeadershipNovember 29th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
